Summary
In 114 subjects with Type 1 (insulin-dependent) diabetes mellitus the nocturnal insulin requirements to maintain euglycaemia were assessed by means of i. v. insulin infusion by a Harvard pump. The insulin requirements decreased after midnight to a nadir of 0.102±0.03 mU·kg−1·min−1 at 02.40 hours. Thereafter, the insulin requirements increased to a peak of 0.135±0.06mU·kg−1·min−1 at 06.40 hours (p<0.05). The dawn phenomenon (increase in insulin requirements by more than 20% after 02.40 hours lasting for at least 90 min) was present in 101 out of the 114 diabetic subjects, and its magnitude (% increase in insulin requirements between 05.00–07.00 hours vs that between 01.00–03.00 hours) was 19.4±0.54% and correlated inversely with the duration of diabetes (r = −0.72, p<0.001), but not with age. The nocturnal insulin requirements and the dawn phenomenon were highly reproducible on three separate nights. In addition, glycaemic control, state of counterregulation to hypoglycaemia and insulin sensitivity all influenced the magnitude of the dawn phenomenon as follows. In a subgroup of 84 subjects with Type 1 diabetes, the multiple correlation analysis showed that not only duration of diabetes (t = −9.76, p<0.0001), but also % HbA1 significantly influenced the magnitude of the dawn phenomenon (t = 2.03, p<0.05). After 5–9 months of intensive therapy, the magnitude of the dawn phenomenon decreased from 24+-2% to 18±2% (p<0.05) in seven Type 1 diabetic subjects with initially poor glycaemic control, whereas it increased from 17±2% to 24±3% (p<0.05) in five Type 1 diabetic subjects in whom glycaemic control had deteriorated for 2 weeks. In 18 Type 1 diabetic subjects the magnitude of the dawn phenomenon correlated with the indices of adequate glucose counterregulation, namely plasma glucose concentration at the hypoglycaemic nadir (r = −0.79) and the rate of plasma glucose recovery from hypoglycaemia (r = −0.74) (both p<0.01). Finally, in 10 diabetic subjects in whom insulin sensitivity was examined by the euglycaemic glucose clamp technique, there was a correlation between the residual rate of hepatic glucose production (r = 0.78, p<0.005) as well as between the rate of peripheral glucose utilization and the magnitude of the dawn phenomenon (r = −0.70, p<0.025). In conclusion, the dawn phenomenon is a very frequent event in Type 1 diabetes; its magnitude (∼20%) is much lower than that indicated by previous Biostator studies; it is highly reproducible from day to day; it is influenced by the duration of diabetes, glycaemic control, state of the counterregulation system to hypoglycaemia and insulin sensitivity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Deckert T, Lorup B (1976) Regulation of brittle diabetes by a pre-planned insulin infusion programme. Diabetologia 12: 573–579
Clarke WL, Haymond MW, Santiago JV (1980) Overnight basal requirements in fasting insulin-dependent diabetics. Diabetes 29: 78–80
De Feo P, Perriello G, Ventura M, Calcinaro F, Basta G, Lolli C, Cruciani C, Dell'Olio A, Santeusanio F, Brunetti P, Bolli GB (1986) Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon. Diabetologia 29: 475–480
Bolli GB, Gerich JE (1984) The “Dawn Phenomenon” — a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 310: 746–750
Atiea JA, Ryder RRJ, Vora J, Owens DR, Luzio SD, Williams S, Hayes TM (1987) Dawn phenomenon: its frequency in noninsulin-dependent diabetic patients on conventional therapy. Diabetes Care 10: 461–465
Dimitriadis G, Vlachonikolis IG, Hatziagellaki E, Linos A, Kodonouri O, Alexopoulos E, Raptis S (1988) The dawn phenomenon in patients with type II diabetes mellitus. Diab Nutr Metab 1: 37–41
Taskinen MR, Sane T, Helve E, Karonen SL, Nikkila EA, Yki-Jarvinen H (1989) Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes 38: 580–588
Shapiro T, Vancauter E, Tillil H, Rubenstein A, Polonsky K (1989) The “dawn phenomenon” in NIDDM: an all night decrease in glucose tolerance. Diabetes 38 [Suppl 2]: 3A
Schmidt MI, Lin QX, Gwynne JT, Jacob S (1984) Fasting early morning rise in peripheral insulin: evidence of the dawn phenomenon in nondiabetics. Diabetes Care 7: 32–35
Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura M, Calcinaro F, Lolli C, Campbell P, Brunetti P, Gerich JE (1984) Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 33: 1150–1153
Campbell PJ, Bolli GB, Cryer PE, Gerich JE (1985) Sequence of events during development of the dawn phenomenon in insulin-dependent diabetes mellitus. Metabolism 34: 1100–1104
Koivisto VA, Yki-Yarvinen H, Helve E, Karonen SL, Pelkonen R (1986) Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 35: 78–82
Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB (1990) Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33: 52–59
Campbell PJ, Bolli GB, Cryer PE, Gerich JE (1985) Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus: accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 312: 1473–1479
Davidson MB, Harris MD, Ziel FH, Rosenberg CS (1988) Suppression of sleep-induced growth hormone secretion by anticholinergic agents abolishes dawn phenomenon. Diabetes 37: 166–171
Boyle PJ, Avogaro A, Smith L, Shah LD, Bier DM, Cryer PE, Santiago JU (1989) Absence of the dawn phenomenon and abnormal lipolysis in GH deficient IDDMs. Diabetes 38 [Suppl. 2]: 3A
Campbell P, Gerich JE (1986) Occurrence of the dawn phenomenon without a change in insulin clearance in patients with insulin-dependent diabetes mellitus. Diabetes 35: 749–752
Widmer A, Keller U, Pasquel U, Berger W (1988) Alterations in insulin clearance and hepatic blood flow during the night do not contribute to the dawn phenomenon in type 1 diabetes. Horm Res 29: 197–201
Bolli GB (1988) The dawn phenomenon: its origin and contribution to early morning hyperglycaemia in diabetes mellitus. Diab Metab 14: 675–686
Cryer P, Gerich J (1985) Glucose counterregulation, hypoglycemia, and intensive insulin therapy. N Engl J Med 313: 232–241
Bolli GB (1989) The pharmacokinetics basis of insulin therapy in diabetes mellitus. Diab Res Clin Pract 6: S3-S16
Faber O, Binder C (1985) C-peptide response to glucagon: a test for the residual B-cell function in diabetes mellitus. Diabetes 26: 605–610
Trivelli LA, Ranney HM, Lai HT (1971) Haemoglobin components in patients with diabetes mellitus. N Engl J Med 284: 353–357
Bolli G, De Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P (1982) Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycemia in type 1 diabetes: evidence foran effect mediated by beta-adrenoreceptors. Diabetes 31: 641–647
Bolli G, De Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P, Gerich JE (1983) Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32: 134–141
De Feo P, Bolli G, Perriello G, De Cosmo S, Compagnucci P, Angeletti G, Santeusanio F, Gerich JE, Motolese M, Brunetti P (1983) The adrenergic contribution to glucose counterregulation in type 1 diabetes mellitus: dependency on A-cell function and mediation through beta-2-adrenergic receptors. Diabetes 32: 887–893
Bolli G, De Feo P, Perriello G, De Cosmo S, Compagnucci P, Santeusanio F, Brunetti P, Unger RH (1984) Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man: role of beta-cell and arterial hyperinsulinemia. J Clin Invest 73: 917–922
Bolli G, De Feo P, De Cosmo S, Perriello G, Ventura MM, Massi Benedetti M, Santeusanio F, Gerich JE, Brunetti P (1984) A reliable and reproducible test for adequate glucose counterregulation in type 1 (insulin-dependent) diabetes mellitus. Diabetes 33: 732–737
Bolli G, De Feo P, De Cosmo S, Perriello G, Angeletti G, Ventura MM, Santeusanio F, Brunetti P, Gerich JE (1984) Effects of long-term optimization and short-term deterioration of glycemic control on glucose counterregulation in type 1 (insulin-dependent) diabetes mellitus. Diabetes 33: 394–400
Bolli GB, Perriello G, De Feo P, Ventura MM, Calafiore R, Calcinaro F, Brunetti P (1987) La resistenza insulinica nel diabate mellito di tipo 1. Effetti della terapia insulinica. Atti 11 Congr Naz Soc Ital Diabetol, Monduzzi, Bologna, pp 33–44
Perriello G, Torlone E, Di Santo S, Fanelli C, De Feo P, Santeusanio F, Brunetti P, Bolli GB (1988) Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 31: 811–815
McGuire E, Helderman J, Tobin R, Andres R, Berman M (1976) Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41: 565–573
Compagnucci P, Cartechini MG, Bolli G, De Feo P, Santeusanio F, Brunetti P (1981) The importance of determing irreversiblyglycosilated haemoglobin in diabetics. Diabetes 30: 607–612
Andres R, Swerdloff I, Pozefsky T, Coleman D (1986) Normal feedback technique for the control of blood glucose concentration. In: Skeggs LT Jr (ed) Automation in analytical chemistry. Mediad, New York, pp 486–491
Rizza RA, Cryer PE, Gerich JE (1979) Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation: effects of somatostatin and combined a- and b-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 64: 62–71
Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH (1977) Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 26: 22–29
De Bodo R, Steele R, Altzuler N, Dunn A, Bishop J (1963) On the hormonal regulation of carbohydrate metabolism: studies with C 14 glucose. Rec Progr Horm Res 19: 445–448
Miles J, Haymond M, Gerich JE (1982) Effects of free fatty acids, insulin, glucagon, and adrenaline on ketone body production in humans. In: Metabolic Acidosis, Ciba Foundation Symposium 87. Pitman Books, London, pp 192–213
Cobelli C, Mari A, Ferrannini E (1987) The non-steady state problem: error analysis of Steele's model and new developments for glucose kinetics. Am J Physiol 252: E679-E689
De Fronzo RA (1988) The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667–687
Zar J (1984) Statistical analysis. Prentice Hall, Englewood Cliffs, NJ
Kerner W, Navaascués I, Torres AA, Pfeiffer EF (1984) Studies on the pathogenesis of the dawn phenomenon in insulin-dependent diabetic patients. Metabolism 33: 458–464
Skor DA, White NH, Thomas L, Shah SD, Cryer PE, Santiago JV (1983) Examination of the role of the pituitary-adrenocortical axis, counterregulatory hormones, and insulin clearance in variable nocturnal insulin requirements in insulin-dependent diabetes. Diabetes 32: 403–407
Campbell PJ, Bolli GB, Gerich JE (1988) Prevention of the dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog. Metabolism 37: 34–37
Brennan JR, Gebhart SSP, Blackard WG (1985) Pump-induced insulin aggregation: a problem with the Biostator. Diabetes 34: 353–359
Clore JN, Nestler JE, Blackard WG (1989) Sleep-associated fall in glucose disposal and hepatic glucose output in normal humans: putative signaling mechanism linking peripheral and hepatic events. Diabetes 38: 285–290
Trovati M, Lorenzati R, Carta Q, Cavalot F, Vitali S, Caselle MT, Pagani A, Pagano G, Lenti G (1982) Overnight changes in insulin requirements assessed by the artificial pancreas in insulin-dependent male diabetics. IRCS Med Sci 10: 368–369
Calabrese G, Bueti A, Santeusanio F, Giombolini A, Zega G, Angeletti G, Cartechini MG, Brunetti P (1982) Continuous subcutaneous insulin infusion treatment in insulin-dependent diabetic patients: a comparison with conventional optimized treatment in a long-term study. Diabetes Care 5: 457–465
Yki-Yarvinen H, Koivisto VA (1986) Natural course of insulin resistance in type I diabetes. N Engl J Med 315: 224–230
Unger R, Grundy S (1985) Hyperglycaemia as an inducer as well as a consequence of impaired islet function and insulin resistance: implication for the management of diabetes. Diabetologia 28: 119–121
Bending JJ, Pickup JC, Collins ACG, Keen H (1985) Rarity of a marked “dawn phenomenon” in diabetic subjects treated by continuous subcutaneous insulin infusion. Diabetes Care 8: 28–33
Gale EAM, Kurtz AB, Tattersall RB (1980) In search of the Somogyi effect. Lancet II: 279–282
Francis AJ, Home PD, Hanning I, Alberti KGMM, Turnbridge WMG (1983) Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J 286: 1173–1176
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perriello, G., De Feo, P., Torlone, E. et al. The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 34, 21–28 (1991). https://doi.org/10.1007/BF00404020
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00404020